https://de.marketscreener.com/kurs/aktie/CNS-PHARMACEUTICALS-INC-73950581/news/CNS-Pharmaceuticals-erhalt-die-Zulassung-fur-die-Zulassungsstudie-von-Berubicin-zur-Behandlung-von-40215050/?utm_source=telegram&utm_medium=social&utm_campaign=share